Please login to the form below

Not currently logged in
Email:
Password:

The Editors blog

An inside look at what’s happening within the pharma industry and across the PMGroup from the PMLiVE editorial team

A sharper focus

The enthusiasm for massive M&A deals is set to redraw industry boundaries

The industry's reawakened enthusiasm for massive M&A deals is set to redraw industry boundaries - particularly if Pfizer is eventually successful with its huge $106bn proposal to acquire AstraZeneca.

There's certainly been no shortage of big deals this month, as the likes of Bristol-Myers Squibb, Lundbeck and Bayer struck out on the acquisition trail.

Perhaps the most intriguing element of this sudden rash of M&A activity was the $16bn Novartis-GlaxoSmithKline 'asset swap', which will see Novartis pick up GSK's oncology portfolio, hand the British company most of its vaccines interests and merge its consumer healthcare business with that of GSK.

The deal will redefine the identity of GSK and Novartis over time and finds further reflection this month in other developments. Merck & Co decided to step away from consumer healthcare, selling its interests in the area - and brands such as Claritin - to Bayer for $14.2bn, and Reckitt Benckiser is considering its pharma future.

Coming after the Abbott/AbbVie and Pfizer/Zoetis splits of the last 18 months, we should expect more of these kinds of deals as companies seek to ruthlessly sharpen their focus.

  • This article was originally published as the editor's comment in PME May 2014


Article by
Dominic Tyer

editorial director of PMGroup

16th May 2014

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics